OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small Cell Lung Cancer

被引：0
|
作者：
Tan, D. S. W. [1 ]
Amin, N. [2 ]
Madondo, M.
Chapaneri, J. [3 ]
Tang, K. H. [4 ]
Taylor, R. [3 ]
Mok, T. [5 ]
机构：
[1] Natl Canc Ctr Singapore, Singapore, Singapore
[2] AstraZeneca, New York, NY USA
[3] AstraZeneca, Cambridge, England
[4] AstraZeneca, Boston, MA USA
[5] Chinese Univ Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
osimertinib; non-small cell lung cancer; amivantamab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-17
引用
收藏
页码：S338 / S339
页数：2
相关论文
共 50 条
  • [1] Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
    Hasan, Nazmul
    Nagasaka, Misako
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2025, 19 (03) : 223 - 232
  • [2] MARIPOSA: phase 3 study of first-line amivantamab plus lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer
    Cho, Byoung Chul
    Felip, Enriqueta
    Hayashi, Hidetoshi
    Thomas, Michael
    Lu, Shun
    Besse, Benjamin
    Sun, Tao
    Martinez, Melissa
    Sethi, Seema N.
    Shreeve, S. Martin
    Spira, Alexander, I
    FUTURE ONCOLOGY, 2022, 18 (06) : 639 - 647
  • [3] A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.
    Giaccone, G
    Lechevalier, T
    Thatcher, N
    Smit, E
    Janmaat, M
    Rodriguez, J
    Oulid-Aissa, D
    Soria, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 638S - 638S
  • [4] A Phase Ii Study Of Carboplatin And Weekly Paclitaxel Combined With Bevacizumab For The First-Line Treatment Of Advanced Non-Small Cell Lung Cancer
    Kubota, T.
    Okano, Y.
    Sakai, M.
    Takaoka, M.
    Tsukuda, T.
    Anabuki, K.
    Kawase, S.
    Miyamoto, S.
    Ohnishi, H.
    Urata, T.
    Takeuchi, E.
    Ogushi, F.
    Yokoyama, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [5] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [6] Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial
    Radhakrishnan, A.
    Bitran, J. D.
    Milton, D. T.
    Tolzien, K.
    Hallmeyer, S.
    Nabhan, C.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (04) : 439 - 444
  • [7] Phase II trial of satraplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer
    Shipley, D.
    Spigel, D. R.
    Cavanaugh, C.
    Moore, Y.
    Hainsworth, J. D.
    Jones, S.
    Burris, H. A., III
    Sade, L.
    Yardley, D. A.
    Greco, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer:: a phase II trial
    Laack, E
    Mende, T
    Benk, J
    Chemaissani, A
    Scholtze, J
    Lorenz, C
    Niestroy, A
    Dalhoff, K
    Müller, T
    Walter, T
    Dürk, H
    Edler, L
    Hossfeld, DK
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (05) : 583 - 590
  • [9] Erlotinib in First-line Therapy for Non-small Cell Lung Cancer: A Prospective Phase II Study
    Choi, Dae Ro
    Lee, Dae Ho
    Choi, Chang-Min
    Kim, Sang-We
    Suh, Cheolwon
    Lee, Jung-Shin
    ANTICANCER RESEARCH, 2011, 31 (10) : 3457 - 3462
  • [10] Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer
    Hyeong Su Kim
    Jung Han Kim
    Byounghoon Kim
    Hyun Chang Choi
    Jung Hye Kwon
    Dae Ro Choi
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1591 - 1597
12345